Silo Pharma Files 8-K: Director Changes, Officer Appointments

TL;DR

Silo Pharma 8-K: Director out, new director in, new officer appointed, and votes coming up.

AI Summary

On October 24, 2025, Silo Pharma, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election of a new director, and the appointment of a new officer. Additionally, the filing covers compensatory arrangements for certain officers and the submission of matters to a vote of security holders. The report also includes financial statements and exhibits.

Why It Matters

Changes in directorship and officer appointments can signal shifts in company strategy or governance, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in leadership and upcoming shareholder votes introduce uncertainty, which can be a medium-risk factor for investors.

Key Players & Entities

• Silo Pharma, Inc. (company) — Registrant
• October 24, 2025 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 001-41512 (identifier) — SEC File Number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar

Filing Documents

• ea0262461-8k_silopharma.htm (8-K) — 41KB
• ea026246101ex10-1_silopharma.htm (EX-10.1) — 10KB
• 0001213900-25-102222.txt ( ) — 216KB
• silo-20251024.xsd (EX-101.SCH) — 3KB
• silo-20251024_lab.xml (EX-101.LAB) — 33KB
• silo-20251024_pre.xml (EX-101.PRE) — 22KB
• ea0262461-8k_silopharma_htm.xml (XML) — 3KB

02 Departure of Directors or Certain Officers; Election of

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the Annual Meeting (as defined below) on October 24, 2025, the shareholders of Silo Pharma, Inc. (the "Company") approved an amendment to the Silo Pharma Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan (the "Plan Amendment') to increase the number of shares of common stock reserved for issuance thereunder to 1,400,000 shares from 470,000 shares. The foregoing descriptions of the Plan Amendment is not complete and are qualified in its entirety by reference to the full text of the Plan Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

07 Submission of Matters to a Vote

Item 5.07 Submission of Matters to a Vote of Security Holders. On October 24, 2025, the Company held its annual meeting of shareholders, (the "Annual Meeting") for the purpose of holding a shareholder vote on the proposals set forth below. A total of 5,142,415 shares of the Company's common stock constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. At the Annual Meeting, the Company's shareholders (i) re-elected each of Eric Weisblum, Wayne Linsley, Kevin Munoz and Jeff Pavell as members of the Company's board of directors to serve until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death; (ii) ratified the appointment of Salberg & Company, P.A. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025; (iii) approved the grant of discretionary authority to the Company's board of directors (the "Board") to file articles of amendment to the Company's articles of incorporation (the "Articles of Incorporation") to effect a reverse split of the Company's issued common stock at a ratio that is not less than 1-for-2 and not greater than 1-for-20, without reducing the authorized number of shares of the Company's common stock, with the exact ratio to be selected by the Board in its discretion and to be effected, if at all, in the sole discretion of the Board at any time following shareholder approval of the amendment to the our Articles of Incorporation and before October 24, 2026 without further approval or authorization of the Company's shareholders (the "Reverse Stock Split Proposal"); (iv) approved the Plan Amendment; and (v) approved the authorization for the adjournment of the Annual Meeting if necessary or appropriate, including to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting or adjournme

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 First Amendment to the Silo Pharma, Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILO PHARMA, INC. Date: October 24, 2025 By: /s/ Eric Weisblum Eric Weisblum Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR